trans-Epoxyocimene is an oxidized ocimene-type monoterpene best documented in AromaForge as a wormwood chemotype marker rather than as a well-characterized standalone active. Live sources support strong identity data from NIST and repeated occurrence in Artemisia absinthium, including an archive-linked survey that reported trans-epoxyocimene from trace levels up to a major 59.7% of the oil. Public biological evidence is weaker and mostly mixture-level, so this record is best positioned around chemistry, occurrence, and honest gaps rather than direct wellness claims.
Chemical identity and composition
NIST lists trans-Epoxyocimene as C10H16O with InChIKey DUBZPCHJCIFTKB-ZJUUUORDSA-N and gives the alternate names (E)-beta-ocimene epoxide, (E)-ocimenoxide, and E-ocimene oxide. In the local archive it is currently represented in common wormwood, where the cited European survey reported 0.1-59.7% with a mean of 5.01%, supporting its relevance as a genuine chemotype-defining constituent rather than a rare trace artifact.
Aroma and practical use
- Use the recorded green, herbal, fresh, terpenic, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2003 Planta Medica abstract reported that French Artemisia absinthium oils containing epoxyocimene-rich chemistry inhibited the growth of Candida albicans and Saccharomyces cerevisiae var. chevalieri.
Europe PMC's abstract describes French wormwood oils with (Z)-epoxyocimene and chrysanthenyl acetate as major components and reports antifungal screening results for the thujone-free French samples, but it does not isolate trans-Epoxyocimene as the sole active.
This experimental finding does not establish benefit, dose or safety in people using this blend.
An archive-linked 2006 European survey reported trans-Epoxyocimene in Artemisia absinthium oils at 0.1-59.7% with a mean of 5.01%, confirming that it can be a major natural-occurrence marker in wormwood.
The survey examined wormwood material from multiple European origins and documented wide chemotype variability, including strongly epoxyocimene-rich samples.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo constituent-specific IFRA standard, RIFM safety assessment, or human tolerability study was verified for isolated trans-Epoxyocimene in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the accessible bioactivity literature is mixture-level, copy should not imply that isolated trans-Epoxyocimene independently delivers the antifungal or wormwood-related effects reported for whole oils.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No reliable public CAS number for isolated trans-Epoxyocimene was verified in the reviewed sources, so this record leaves CAS as null.
- This pass did not locate isolated-compound pharmacology or toxicology studies that cleanly separate trans-Epoxyocimene from broader wormwood or other essential-oil mixtures.
- Most published wormwood safety discussion is driven by thujone exposure rather than by trans-Epoxyocimene specifically.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.